PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsTenofovir disoproxil
Viread(tenofovir disoproxil)
Cimduo, Complera, Delstrigo, Efavirenz / / Tenofovir Disoproxil, Efavirenz / Emtricitabine / Tenofovir Disoproxil, Emtricitabine / Tenofovir Disoproxil, Eviplera, Stribild, Symfi, Tenofovir Disoproxil, Truvada, Viread (tenofovir disoproxil) is a small molecule pharmaceutical. Tenofovir disoproxil was first approved as Viread on 2001-10-26. It is used to treat chronic hepatitis b and HIV in the USA. It has been approved in Europe to treat chronic hepatitis b and HIV infections.
Download report
Favorite
BMS
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
urogenital diseasesD000091642
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Tenofovir disoproxil, Viread (discontinued: Tenofovir disoproxil)
Combinations
Cimduo, Complera, Delstrigo, Efavirenz, emtricitabine, tenofovir disoproxil, Efavirenz, lamivudine tenofovir disoproxil, Emtricitabine tenofovir disoproxil, Emtricitabine, rilpivirine tenofovir disoproxil, Stribild, Symfi, Truvada (discontinued: Atripla, Efavirenz, lamivudine tenofovir disoproxil, Efavirenz; emtricitabine tenofovir disoproxil, Efavirenz; emtricitabine; tenofovir disoproxil, Emtricitabine tenofovir disoproxil, Lamivudine tenofovir disoproxil, Symfi lo, Temixys)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lamivudine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
CIMDUOMylanN-022141 RX2018-02-28
1 products, RLD, RS
Show 2 discontinued
Efavirenz
+
Lamivudine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
SYMFIMylanN-022142 RX2018-03-22
1 products, RLD, RS
Show 3 discontinued
Doravirine
+
Lamivudine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
DELSTRIGOMerck & CoN-210807 RX2018-08-30
1 products, RLD, RS
Efavirenz
+
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
ATRIPLAGilead SciencesN-021937 DISCN2006-07-12
1 products, RLD
Hide discontinued
Emtricitabine
+
Rilpivirine hydrochloride
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
COMPLERAGilead SciencesN-202123 RX2011-08-10
1 products, RLD, RS
Cobicistat
+
Elvitegravir
+
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
STRIBILDGilead SciencesN-203100 RX2012-08-27
1 products, RLD, RS
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
TRUVADAGilead SciencesN-021752 RX2004-08-02
4 products, RLD, RS
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
VIREADGilead SciencesN-021356 RX2001-10-26
4 products, RLD, RS
VIREADGilead SciencesN-022577 RX2012-01-18
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
atriplaNew Drug Application2017-01-23
cimduoNew Drug Application2021-02-15
compleraNew Drug Application2025-07-16
complera accessExport only2025-07-16
delstrigoNew Drug Application2025-10-29
efavirenz, emtricitabine and tenofovir disoproxil fumarateANDA2025-11-04
efavirenz, lamivudine and tenofovir disoproxil fumarateANDA2024-05-07
emtricitabine and tenofovir disoproxil fumarateANDA2026-02-01
emtricitabine, rilpivirine, tenofovir disoproxil fumarateANDA2024-12-14
stribildNew Drug Application2025-02-04
Show 7 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hiv infectionsEFO_0000764D015658B20
hiv—D006678O98.7
acquired immunodeficiency syndromeEFO_0000765D000163B20
chronic hepatitis bEFO_0004239D019694B18.1
hepatitis b—D006509—
hiv-1—D015497—
Agency Specific
FDA
EMA
Expiration
Code
DORAVIRINE / LAMIVUDINE / TENOFOVIR DISOPROXIL FUMARATE, DELSTRIGO, MSD MERCK CO
2025-01-27NPP
2023-08-30NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate, Delstrigo, Msd Merck Co
106032822036-11-29DP
108427512036-11-29DP
84869752031-10-07DS, DPU-2395, U-2629, U-3307
Emtricitabine / Rilpivirine Hydrochloride / Tenofovir Disoproxil Fumarate, Complera, Gilead Sciences Inc
108571022033-01-14DP
88413102025-12-09DPU-257
71258792025-04-21DS, DPU-257
80805512023-04-11DS, DP
Cobicistat / Elvitegravir / Emtricitabine / Tenofovir Disoproxil Fumarate, Stribild, Gilead Sciences Inc
100397182032-10-06DP
86332192030-04-30DPU-257
81483742029-09-03DS, DPU-1279
98912392029-09-03DPU-257
76357042026-10-26DS, DPU-257
89811032026-10-26DS, DP
71762202026-08-27DS, DPU-257
85923972024-01-13DPU-248, U-257, U-541, U-750, U-1170
87162642024-01-13DPU-257
94570362024-01-13DPU-257
97441812024-01-13DPU-257
Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate, Atripla, Gilead Sciences
85981852029-04-28DP
90181922026-06-13U-750, U-1170
95454142026-06-13DPU-750, U-1170
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AF: Nucleoside and nucleotide reverse transcriptase inhibitors
— J05AF07: Tenofovir disoproxil
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR03: Tenofovir disoproxil and emtricitabine
— J05AR06: Emtricitabine, tenofovir disoproxil and efavirenz
— J05AR08: Emtricitabine, tenofovir disoproxil and rilpivirine
— J05AR09: Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
— J05AR11: Lamivudine, tenofovir disoproxil and efavirenz
— J05AR12: Lamivudine and tenofovir disoproxil
— J05AR24: Lamivudine, tenofovir disoproxil and doravirine
— J05AR27: Lamivudine, tenofovir disoproxil and dolutegravir
HCPCS
No data
Clinical
Clinical Trials
1371 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2055137180155143639
Hepatitis bD006509——2665447787292
HepatitisD006505—K75.92354396772248
Chronic hepatitis bD019694EFO_0004239B18.12457356271242
HivD006678—O98.73024407351213
Hepatitis aD006506EFO_0007305B151846325360203
Acquired immunodeficiency syndromeD000163EFO_0000765B202133523951186
Chronic hepatitisD006521—K73.91027183231113
InfectionsD007239EFO_0000544—32328142184
Healthy volunteers/patients———312—8242
Show 109 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis dD003699EFO_0007304——71—210
Immunologic deficiency syndromesD007153—D84.9—34—18
Covid-19D000086382—U07.1—36—28
Breast feedingD001942———13—36
Liver diseasesD008107EFO_0001421K70-K772—1—25
HomosexualityD006716————1—34
Liver transplantationD016031EFO_0010682——11—24
Chronic hepatitis dD019701———31——4
Metabolic syndromeD024821EFO_0000195E88.810—11—24
HyperlipidemiasD006949EFO_0003774E78.5——1—12
Show 14 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gender identityD005783——11——34
Kidney diseasesD007674EFO_0003086N08—1——34
HypertensionD006973EFO_0000537I10—1——23
Behavior and behavior mechanismsD001520——11——23
Biliary liver cirrhosisD008105—K74.3—1——12
PharmacokineticsD010599——11——12
Directly observed therapyD023801———2———2
Metabolic diseasesD008659EFO_0000589E88.9—1——12
Ebola hemorrhagic feverD019142EFO_0007243A98.4—1———1
ParasitemiaD018512——11———1
Show 17 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Insulin resistanceD007333EFO_0002614E88.8193————3
Heart disease risk factorsD000082742——1———12
Lipid metabolism disordersD052439——1———12
Contraception behaviorD003268——1———12
HepacivirusD016174——1———12
Gender dysphoriaD000068116—F641————1
TransgenesD019076——1————1
Bronchiolitis obliterans syndromeD000092122—D89.8111————1
Amyotrophic lateral sclerosisD000690EFO_0000253G12.211————1
Latent tuberculosisD055985—Z22.71————1
Show 3 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Risk reduction behaviorD040242——————44
AgingD000375GO_0007568R41.81————33
Sustained virologic responseD000072230——————22
Bone densityD015519EFO_0003923M85————22
Acute kidney injuryD058186—N17————22
Portal hypertensionD006975EFO_0000666K76.6————22
Esophageal and gastric varicesD004932EFO_0009545I85————22
Self efficacyD020377——————22
Retinal diseasesD012164—H35.9————22
GonorrheaD006069DOID_7551A54————22
Show 35 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTenofovir disoproxil
INN—
Description
Tenofovir (anhydrous) is a member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection. It has a role as a HIV-1 reverse transcriptase inhibitor, an antiviral drug and a drug metabolite. It is a member of phosphonic acids and a nucleoside analogue. It is a conjugate acid of a tenofovir(1-).
Classification
Small molecule
Drug classantivirals
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C
Identifiers
PDB—
CAS-ID147127-20-6
RxCUI117466
ChEMBL IDCHEMBL1538
ChEBI ID63717
PubChem CID464205
DrugBankDB00300
UNII ID—
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Complera – Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Delstrigo – Merck & Co
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Atripla – Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Truvada – Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Stribild – Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Viread – Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
Black-box warning for: Atripla, Cimduo, Complera, Complera access, Delstrigo, Efavirenz, emtricitabine and tenofovir disoproxil fumarate, Efavirenz, lamivudine and tenofovir disoproxil fumarate, Emtricitabine and tenofovir disoproxil fumarate, Emtricitabine, rilpivirine, tenofovir disoproxil fumarate, Stribild, Symfi, Tenofovir disoproxil fumarate, Tenofovir disproxil fumarate, Truvada, Truvada access, Viread, Viread access
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
87,843 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use